Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Competition and efficiency in the end stage renal disease program.

Held PJ, Pauly MV.

J Health Econ. 1983 Aug;2(2):95-118.

PMID:
10263967
2.

Dialysis outcomes in works. HCFA may set quality, practice guidelines for ESRD program.

Gardner J.

Mod Healthc. 1997 Feb 3;27(5):64-5. No abstract available.

PMID:
10164704
3.

Competition under fixed prices: effects on patient selection and service strategies by hemodialysis providers.

Farley DO.

Med Care Res Rev. 1996 Sep;53(3):330-49. No abstract available.

PMID:
10159932
4.
5.

Some of the small print on managed care proposals for end-stage renal disease.

Hirth RA, Held PJ.

Adv Ren Replace Ther. 1997 Oct;4(4):314-24. Review.

PMID:
9356683
6.

Effect of the dialysis membrane on mortality of chronic hemodialysis patients.

Hakim RM, Held PJ, Stannard DC, Wolfe RA, Port FK, Daugirdas JT, Agodoa L.

Kidney Int. 1996 Aug;50(2):566-70.

7.

The dose of hemodialysis and patient mortality.

Held PJ, Port FK, Wolfe RA, Stannard DC, Carroll CE, Daugirdas JT, Bloembergen WE, Greer JW, Hakim RM.

Kidney Int. 1996 Aug;50(2):550-6.

8.

Effect of dialyzer reuse on survival of patients treated with hemodialysis.

Feldman HI, Kinosian M, Bilker WB, Simmons C, Holmes JH, Pauly MV, Escarce JJ.

JAMA. 1996 Aug 28;276(8):620-5. Erratum in: JAMA 1996 Dec 4;276(21):1724.

PMID:
8773634
9.

The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis.

Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM.

N Engl J Med. 1993 Sep 30;329(14):1001-6.

10.

Analysis of the association of dialyzer reuse practices and patient outcomes.

Held PJ, Wolfe RA, Gaylin DS, Port FK, Levin NW, Turenne MN.

Am J Kidney Dis. 1994 May;23(5):692-708.

PMID:
8172212
11.

Refining a case-mix measure for nursing homes: Resource Utilization Groups (RUG-III).

Fries BE, Schneider DP, Foley WJ, Gavazzi M, Burke R, Cornelius E.

Med Care. 1994 Jul;32(7):668-85.

PMID:
8028403
12.

The production of dialysis by for-profit versus not-for-profit freestanding renal dialysis facilities.

Griffiths RI, Powe NR, Gaskin DJ, Anderson GF, de Lissovoy GV, Whelton PK.

Health Serv Res. 1994 Oct;29(4):473-87.

13.

From the Health Care Financing Administration.

Vladeck BC.

JAMA. 1995 Jun 28;273(24):1896. No abstract available.

PMID:
7783287
14.

Risk contracts in managed mental health care.

Frank RG, McGuire TG, Newhouse JP.

Health Aff (Millwood). 1995 Fall;14(3):50-64.

15.

A national survey of the arrangements managed-care plans make with physicians.

Gold MR, Hurley R, Lake T, Ensor T, Berenson R.

N Engl J Med. 1995 Dec 21;333(25):1678-83.

16.

Price of dialysis, unit staffing, and length of dialysis treatments.

Held PJ, GarcĂ­a JR, Pauly MV, Cahn MA.

Am J Kidney Dis. 1990 May;15(5):441-50.

PMID:
2333866
17.

Mortality and duration of hemodialysis treatment.

Held PJ, Levin NW, Bovbjerg RR, Pauly MV, Diamond LH.

JAMA. 1991 Feb 20;265(7):871-5.

PMID:
1899455
18.

The Medicare cost of renal dialysis. Evidence from a statistical cost function.

Dor A, Held PJ, Pauly MV.

Med Care. 1992 Oct;30(10):879-91.

PMID:
1405794
Items per page

Supplemental Content

Write to the Help Desk